Befejeződött1. fázis
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema
Key facts
- Where
- Berlin, Bonn, Mainz és Tuebingen, NémetországSee the 4 sites
- Phase
- 1. fázis
Where in Németország
- Charite Universitaetsmedizin Berlin KöRBerlin, NémetországNo longer taking part
- Universitaetsklinikum Bonn AöRBonn, NémetországNo longer taking part
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, NémetországNo longer taking part
- Universitaetsklinikum Tuebingen AöRTuebingen, NémetországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Breye Therapeutics ApS
- Trial code
- EU 2023-503683-16-00
- Record updated
- 2025. január 21.